血清甲氨蝶呤水平用于评估银屑病生化药物依从性
该研究在三级皮肤科中心,用敏感液相色谱-串联质谱法审计口服甲氨蝶呤治疗银屑病患者的生化依从性。银屑病影响全球约2–3%人群,甲氨蝶呤是廉价有效的一线系统用药,约40–50%患者反应良好,但无反应机制尚不清楚。目前尚不确定银屑病患者生化甲氨蝶呤依从性是否欠佳而需干预。
要点
- 银屑病全球患病率约2–3%,甲氨蝶呤为常用一线系统用药。
- 约40–50%患者对甲氨蝶呤反应良好,无反应机制了解不足。
- 用液相色谱-串联质谱法审计口服甲氨蝶呤的生化依从性。
核心结论
- 尚不确定银屑病患者生化甲氨蝶呤依从性是否欠佳并需要干预。
研究设计与样本
- 在三级皮肤科中心对口服甲氨蝶呤治疗银屑病的患者进行生化依从性审计,采用敏感液相色谱-串联质谱法检测血清甲氨蝶呤水平;健康研究管理局确认该审计无需伦理批准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Psoriasis is a common inflammatory skin condition affecting approximately 2–3% of people worldwide. Methotrexate (MTX) is a cheap and effective drug that is often recommended as the first-choice systemic agent for psoriasis. Around 40–50% of patients achieve a good response; however, mechanisms of nonresponse are poorly understood. It is not known whether biochemical MTX adherence in patients with psoriasis is suboptimal and requires intervention. Our aim was to audit biochemical MTX adherence using a sensitive liquid chromatography–tandem mass spectrometry in patients prescribed oral MTX for the treatment of psoriasis at our tertiary dermatology centre. Ethical approval for this audit was not required as confirmed by the Health Research Authority.
引用
- Ra AG, Littlewood Z, Barton A, et al. The use of serum methotrexate level as an assessment of biochemical drug adherence in psoriasis. Br J Dermatol. 2024. PMID: 38454565. doi:10.1093/bjd/ljae096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。